Osteoporosis Prevention With Low Dose Alendronate
Sponsored by University Hospital of Mont-Godinne
About this trial
Last updated 12 years ago
Study ID
MG/OP 001
Status
Completed
Type
Interventional
Phase
Phase 3
Placebo
Yes
Accepting
45 to 60 Years
Female
Not accepting
Healthy Volunteers
Trial Timing
Ended 14 years ago
What is this trial about?
The purpose of this study is to evaluate the efficacy of the intermittent administration
of alendronate in a low dose, 70 mg once every two week, as osteoporosis prevention for
menopausal, osteopenic patients, who don't want or can't receive an oestrogenic
substitution treatment.
What are the participation requirements?
Inclusion Criteria
- 45 to 60 year-old women
- Menopausal since at least 6 months
- Baseline lumbar BMD from -1 till -2.5
Exclusion Criteria
- Bone disease other than osteopenia
- Treatment with selective estrogen receptor modulator (SERMs), calcitonin or hormone replacement therapy within 6 monts prior to randomization
- Former or current treatment with any bisphosphonate or bone forming agents
- Chronic use of oral or iv corticosteroids
- Any diagnosis of malignancy less than 12 months